S100B Is a Potential Disease Activity Marker in Nonsegmental Vitiligo

Area of Science:

• Dermatology
• Immunology
• Biochemistry

Background:

• Vitiligo is a chronic skin depigmentation condition.
• S100B protein, a marker of melanocyte cytotoxicity, is established in melanoma research.
• The role of S100B in vitiligo activity is unexplored.

Purpose of the Study:

• Investigate S100B as a biomarker for vitiligo activity.
• Explore S100B's role in vitiligo pathogenesis.
• Assess S100B inhibition as a potential therapeutic strategy.

Main Methods:

• Measured serum S100B levels in vitiligo patients.
• Correlated S100B levels with disease activity and body surface area.
• Conducted in vitro studies on melanocytes and a vitiligo mouse model.

Main Results:

• Significantly elevated serum S100B in active nonsegmental vitiligo patients.
• S100B levels strongly correlated with affected body surface area.
• Serum S100B predicted disease progression and showed potential for therapeutic targeting.

Conclusions:

• S100B is a potential biomarker for vitiligo disease activity.
• S100B may play a role in vitiligo pathogenesis.
• S100B inhibition presents a novel therapeutic avenue for vitiligo.